INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7701, 17239, 'Metolazone', 'Asthma', 'Thiazide diuretics should be used with caution in patients with history of bronchial asthma as sensitivity reactions may occur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7702, 18087, 'Metolazone', 'Asthma', 'Thiazide diuretics should be used with caution in patients with history of bronchial asthma as sensitivity reactions may occur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7703, 22666, 'Metolazone', 'Asthma', 'Thiazide diuretics should be used with caution in patients with history of bronchial asthma as sensitivity reactions may occur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7704, 26084, 'Metolazone', 'Asthma', 'Thiazide diuretics should be used with caution in patients with history of bronchial asthma as sensitivity reactions may occur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7705, 17239, 'Metolazone', 'Diabetes Mellitus', 'Thiazide diuretics may cause hyperglycemia and glycosuria in patients with diabetes.  They may also precipitate diabetes in prediabetic patients.  These effects are usually reversible following discontinuation of the drugs.  Therapy with thiazide diuretics should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during thiazide therapy, and their antidiabetic regimen adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7706, 18087, 'Metolazone', 'Diabetes Mellitus', 'Thiazide diuretics may cause hyperglycemia and glycosuria in patients with diabetes.  They may also precipitate diabetes in prediabetic patients.  These effects are usually reversible following discontinuation of the drugs.  Therapy with thiazide diuretics should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during thiazide therapy, and their antidiabetic regimen adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7707, 22666, 'Metolazone', 'Diabetes Mellitus', 'Thiazide diuretics may cause hyperglycemia and glycosuria in patients with diabetes.  They may also precipitate diabetes in prediabetic patients.  These effects are usually reversible following discontinuation of the drugs.  Therapy with thiazide diuretics should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during thiazide therapy, and their antidiabetic regimen adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7708, 26084, 'Metolazone', 'Diabetes Mellitus', 'Thiazide diuretics may cause hyperglycemia and glycosuria in patients with diabetes.  They may also precipitate diabetes in prediabetic patients.  These effects are usually reversible following discontinuation of the drugs.  Therapy with thiazide diuretics should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during thiazide therapy, and their antidiabetic regimen adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7709, 17239, 'Metolazone', 'Hyperlipidemias', 'Thiazide diuretics may increase serum triglyceride and cholesterol levels, primarily LDL and VLDL.  Whether these effects are dose-related and sustained during chronic therapy are unknown.  Patients with preexisting hyperlipidemia may require closer monitoring during thiazide therapy, and adjustments made accordingly in their lipid-lowering regimen', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7710, 18087, 'Metolazone', 'Hyperlipidemias', 'Thiazide diuretics may increase serum triglyceride and cholesterol levels, primarily LDL and VLDL.  Whether these effects are dose-related and sustained during chronic therapy are unknown.  Patients with preexisting hyperlipidemia may require closer monitoring during thiazide therapy, and adjustments made accordingly in their lipid-lowering regimen', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7711, 22666, 'Metolazone', 'Hyperlipidemias', 'Thiazide diuretics may increase serum triglyceride and cholesterol levels, primarily LDL and VLDL.  Whether these effects are dose-related and sustained during chronic therapy are unknown.  Patients with preexisting hyperlipidemia may require closer monitoring during thiazide therapy, and adjustments made accordingly in their lipid-lowering regimen', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7712, 26084, 'Metolazone', 'Hyperlipidemias', 'Thiazide diuretics may increase serum triglyceride and cholesterol levels, primarily LDL and VLDL.  Whether these effects are dose-related and sustained during chronic therapy are unknown.  Patients with preexisting hyperlipidemia may require closer monitoring during thiazide therapy, and adjustments made accordingly in their lipid-lowering regimen', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7713, 17239, 'Metolazone', 'Hyperparathyroidism', 'Urinary calcium excretion is decreased by thiazide diuretics during chronic administration.  Pathologic changes in the parathyroid gland with hypercalcemia and hypophosphatemia have been reported during prolonged therapy.  However, the common complications of hyperparathyroidism such as renal lithiasis, bone resorption, and peptic ulceration have not been seen.  Clinicians should be cognizant of these effects when prescribing or administering thiazide therapy to patients with hyperparathyroidism.  These drugs should be discontinued before carrying out tests for parathyroid function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7714, 18087, 'Metolazone', 'Hyperparathyroidism', 'Urinary calcium excretion is decreased by thiazide diuretics during chronic administration.  Pathologic changes in the parathyroid gland with hypercalcemia and hypophosphatemia have been reported during prolonged therapy.  However, the common complications of hyperparathyroidism such as renal lithiasis, bone resorption, and peptic ulceration have not been seen.  Clinicians should be cognizant of these effects when prescribing or administering thiazide therapy to patients with hyperparathyroidism.  These drugs should be discontinued before carrying out tests for parathyroid function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7715, 22666, 'Metolazone', 'Hyperparathyroidism', 'Urinary calcium excretion is decreased by thiazide diuretics during chronic administration.  Pathologic changes in the parathyroid gland with hypercalcemia and hypophosphatemia have been reported during prolonged therapy.  However, the common complications of hyperparathyroidism such as renal lithiasis, bone resorption, and peptic ulceration have not been seen.  Clinicians should be cognizant of these effects when prescribing or administering thiazide therapy to patients with hyperparathyroidism.  These drugs should be discontinued before carrying out tests for parathyroid function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7716, 26084, 'Metolazone', 'Hyperparathyroidism', 'Urinary calcium excretion is decreased by thiazide diuretics during chronic administration.  Pathologic changes in the parathyroid gland with hypercalcemia and hypophosphatemia have been reported during prolonged therapy.  However, the common complications of hyperparathyroidism such as renal lithiasis, bone resorption, and peptic ulceration have not been seen.  Clinicians should be cognizant of these effects when prescribing or administering thiazide therapy to patients with hyperparathyroidism.  These drugs should be discontinued before carrying out tests for parathyroid function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7717, 17239, 'Metolazone', 'Hyperuricemia', 'Thiazide diuretics decrease the rate of uric acid excretion.  Hyperuricemia occurs frequently but is usually asymptomatic and rarely leads to clinical gout except in patients with a history of gout or chronic renal failure.  Therapy with thiazide diuretics should be administered cautiously in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7718, 18087, 'Metolazone', 'Hyperuricemia', 'Thiazide diuretics decrease the rate of uric acid excretion.  Hyperuricemia occurs frequently but is usually asymptomatic and rarely leads to clinical gout except in patients with a history of gout or chronic renal failure.  Therapy with thiazide diuretics should be administered cautiously in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7719, 22666, 'Metolazone', 'Hyperuricemia', 'Thiazide diuretics decrease the rate of uric acid excretion.  Hyperuricemia occurs frequently but is usually asymptomatic and rarely leads to clinical gout except in patients with a history of gout or chronic renal failure.  Therapy with thiazide diuretics should be administered cautiously in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7720, 26084, 'Metolazone', 'Hyperuricemia', 'Thiazide diuretics decrease the rate of uric acid excretion.  Hyperuricemia occurs frequently but is usually asymptomatic and rarely leads to clinical gout except in patients with a history of gout or chronic renal failure.  Therapy with thiazide diuretics should be administered cautiously in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7721, 17239, 'Metolazone', 'Thyroid Diseases', 'Thiazide diuretics may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Clinicians should be cognizant of this effect when prescribing or administering thiazide therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7722, 18087, 'Metolazone', 'Thyroid Diseases', 'Thiazide diuretics may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Clinicians should be cognizant of this effect when prescribing or administering thiazide therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7723, 22666, 'Metolazone', 'Thyroid Diseases', 'Thiazide diuretics may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Clinicians should be cognizant of this effect when prescribing or administering thiazide therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7724, 26084, 'Metolazone', 'Thyroid Diseases', 'Thiazide diuretics may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Clinicians should be cognizant of this effect when prescribing or administering thiazide therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7725, 0, 'Acebutolol', 'Diseases requiring hemodialysis', 'Acebutolol is moderately removed by hemodialysis and should be administered after dialysis when the patient is hemodynamically stable to avoid marked falls in blood pressure.  The hemodynamic status should be closely monitored before and after the dose.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7726, 0, 'Acebutolol', 'Kidney Diseases', 'The active metabolite of acebutolol, diacetolol, is eliminated primarily by the kidney.  Patients with renal impairment may be at greater risk for adverse effects due to metabolite accumulation.  Dosage adjustments are recommended for patients with moderate to severe renal dysfunction (CrCl < 50 mL/min).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7727, 0, 'Acebutolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7728, 0, 'Acebutolol', 'Shock, Cardiogenic', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with hypotension or cardiogenic shock.  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to further depress cardiac output and blood pressure, which can be detrimental in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7729, 0, 'Acebutolol', 'Heart Failure', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with overt congestive heart failure (CHF).  Sympathetic stimulation may be important in maintaining the hemodynamic function in these patients, thus beta-blockade can worsen the heart failure.  However, therapy with beta-blockers may be beneficial and can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Carvedilol, specifically, is indicated for use with these agents in the treatment of mild to severe heart failure of ischemic or cardiomyopathic origin.  There is also increasing evidence that the addition of a beta-blocker to standard therapy can improve morbidity and mortality in patients with advanced heart failure, although it is uncertain whether effectiveness varies significantly with the different agents.  Data from one meta-analysis study suggest a greater reduction of mortality risk for nonselective beta-blockers than for beta-1 selective agents.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7730, 0, 'Acebutolol', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since cardioselectivity is not absolute, larger doses of beta-1 selective agents may demonstrate these effects as well.  Therapy with beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7731, 0, 'Acebutolol', 'Hypersensitivity', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7732, 0, 'Acebutolol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7733, 0, 'Acebutolol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7734, 0, 'Acebutolol', 'Hepatic Insufficiency', 'Acebutolol should be used cautiously in patients with impaired hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7735, 0, 'Acebutolol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7736, 0, 'Acebutolol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7737, 0, 'Acebutolol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7738, 0, 'Acebutolol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7739, 0, 'Acebutolol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7740, 0, 'Acebutolol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7741, 0, 'Acebutolol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7742, 0, 'Acebutolol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7743, 0, 'Acebutolol', 'Asthma', 'Patients with bronchospastic disease, should, in general, not receive beta blockers, including cardioselective beta-blockers.  Because of the relative beta-1 selectivity, cardioselective beta-blockers may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment.  Because beta-1 selectivity is not absolute, the lowest possible dose of these agents should be used.  Consider administering in smaller doses to avoid the higher plasma levels associated with the longer dosing intervals.  If dosage must be increased, dividing the dose should be considered to achieve lower peak blood levels.  It is recommended to have bronchodilators, including beta-2 agonists, readily available or administered concomitantly if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7744, 6075, 'Mexiletine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7745, 8112, 'Mexiletine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7746, 6075, 'Mexiletine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7747, 8112, 'Mexiletine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7748, 6075, 'Mexiletine', 'Sick Sinus Syndrome', 'The use of mexiletine is contraindicated in patients with cardiogenic shock, second- or third-degree AV block in the absence of a functional artificial pacemaker.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7749, 8112, 'Mexiletine', 'Sick Sinus Syndrome', 'The use of mexiletine is contraindicated in patients with cardiogenic shock, second- or third-degree AV block in the absence of a functional artificial pacemaker.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7750, 6075, 'Mexiletine', 'Liver Diseases', 'Mexiletine is extensively metabolized by the liver to minimally active and inactive forms.  The serum concentration of mexiletine is increased and the half-life prolonged in patients with liver impairment.  Elevation of liver enzymes have been reported during the first few weeks of therapy, primarily in patients with congestive heart failure (CHF) or ischemia. Hepatic necrosis, resulting in death, has occurred.   Therapy with mexiletine should be administered cautiously in patients with compromised liver function, CHF or ischemia.  Clinical monitoring of cardiac function (ECG) and liver function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7751, 8112, 'Mexiletine', 'Liver Diseases', 'Mexiletine is extensively metabolized by the liver to minimally active and inactive forms.  The serum concentration of mexiletine is increased and the half-life prolonged in patients with liver impairment.  Elevation of liver enzymes have been reported during the first few weeks of therapy, primarily in patients with congestive heart failure (CHF) or ischemia. Hepatic necrosis, resulting in death, has occurred.   Therapy with mexiletine should be administered cautiously in patients with compromised liver function, CHF or ischemia.  Clinical monitoring of cardiac function (ECG) and liver function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7752, 6075, 'Mexiletine', 'Kidney Diseases', 'Mexiletine is primarily eliminated by the kidney.  Approximately 10% of mexiletine is excreted in the urine unchanged.  Marked changes in urinary pH alter the rate of mexiletine excretion.  Elimination is accelerated with an acidic urinary pH and slowed with an alkaline urinary pH.  Therapy with mexiletine should be administered cautiously in patients with significant renal impairment.  Clinical monitoring of cardiac function (ECG) and renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7753, 8112, 'Mexiletine', 'Kidney Diseases', 'Mexiletine is primarily eliminated by the kidney.  Approximately 10% of mexiletine is excreted in the urine unchanged.  Marked changes in urinary pH alter the rate of mexiletine excretion.  Elimination is accelerated with an acidic urinary pH and slowed with an alkaline urinary pH.  Therapy with mexiletine should be administered cautiously in patients with significant renal impairment.  Clinical monitoring of cardiac function (ECG) and renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7754, 6075, 'Mexiletine', 'Seizures', 'Seizures have been reported rarely during mexiletine therapy in patients with and without a history of seizures.  Therapy with mexiletine should be administered cautiously in patients with or predisposition to seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7755, 8112, 'Mexiletine', 'Seizures', 'Seizures have been reported rarely during mexiletine therapy in patients with and without a history of seizures.  Therapy with mexiletine should be administered cautiously in patients with or predisposition to seizure disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7756, 0, 'Metreleptin', 'Lymphoma', 'Cases of T-cell lymphoma have been reported during treatment with metreleptin in patients with acquired generalized lipodystrophy.  Some, but not all, had immunodeficiency and significant hematologic abnormalities including severe bone marrow abnormalities before the initiation of metreleptin therapy.  However, lymphomas and other lymphoproliferative disorders have also been reported in patients with acquired generalized lipodystrophy who did not receive metreleptin, thus a causal relationship with metreleptin has not been established.  Acquired lipodystrophies are associated with autoimmune disorders, and the latter is associated with an increased risk of malignancies including lymphomas.  Until more information is available, the potential benefits and risks of metreleptin treatment should be carefully considered in patients with acquired generalized lipodystrophy and/or those with significant hematologic abnormalities including leukopenia, neutropenia, bone marrow abnormalities, lymphoma, and/or lymphadenopathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7757, 0, 'Metreleptin', 'Obesity', 'The use of metreleptin is contraindicated in patients with general obesity not associated with congenital leptin deficiency.  Metreleptin has not been shown to be effective in treating general obesity.  Moreover, development of anti-metreleptin antibodies with neutralizing activity has been reported in obese patients treated with metreleptin, the clinical consequences of which have not been well characterized but could include inhibition of endogenous leptin action and loss of metreleptin efficacy.  Worsening metabolic control and/or severe infection have been reported.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7758, 0, 'Metreleptin', 'Autoimmune Diseases', 'Leptin is involved in immune system homeostasis.  Patients with acquired lipodystrophies and leptin deficiency may have autoimmune disorders including autoimmune hepatitis and membranoproliferative glomerulonephritis.  Progression of autoimmune hepatitis and membranoproliferative glomerulonephritis with massive proteinuria and renal failure has occurred in some patients with acquired generalized lipodystrophy treated with metreleptin, a recombinant analog of human leptin.  A causal relationship between metreleptin treatment and the development and/or progression of autoimmune disease has not been established.  Until more information is available, the potential benefits and risks of metreleptin treatment should be carefully considered in patients with autoimmune diseases.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7759, 0, 'Metreleptin', 'Hypoglycemia', 'Metreleptin can cause hypoglycemia.  Caution is advised in patients that suffer from hypoglycemia or in diabetic patients in treatment with oral hypoglycemic agents or insulin.  A dosage adjustment might be needed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7760, 0, 'Arsenic trioxide', 'Long QT Syndrome', 'Arsenic trioxide can cause QTc interval prolongation, complete atrioventricular block, and a torsade de pointes- type ventricular arrhythmia, which can be fatal.  Prior to initiating therapy with arsenic trioxide, assess the QTc interval by electrocardiogram, correct pre- existing electrolyte abnormalities, and consider discontinuing drugs known to prolong QTc interval.  Arsenic trioxide should not be administered to patients with ventricular arrhythmia or prolonged QTc interval.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7761, 0, 'Arsenic trioxide', 'Brain Diseases', 'Serious encephalopathy, including Wernicke''s, has occurred in patients treated with arsenic trioxide injection.  Wernicke''s is a neurologic emergency.  Consider testing thiamine levels in patients at risk for thiamine deficiency.  Administer parenteral thiamine in patients with or at risk for thiamine deficiency.  Monitor patients for neurological symptoms and nutritional status while receiving arsenic trioxide injection.  If encephalopathy is suspected, immediately interrupt arsenic trioxide injection and initiate parenteral thiamine.  Monitor until symptoms resolve or improve and thiamine levels normalize.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7762, 690, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7763, 691, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7764, 692, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7765, 4210, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7766, 4325, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7767, 4894, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7768, 4903, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7769, 4904, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7770, 4905, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7771, 4906, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7772, 4930, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7773, 6077, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7774, 8101, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7775, 8102, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7776, 14075, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7777, 14076, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7778, 14080, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7779, 15559, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7780, 16787, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7781, 17956, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7782, 17957, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7783, 18347, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7784, 19075, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7785, 19077, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7786, 19078, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7787, 19079, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7788, 19085, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7789, 19630, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7790, 22672, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7791, 22676, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7792, 22677, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7793, 22679, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7794, 22680, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7795, 26297, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7796, 28488, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7797, 28489, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7798, 28490, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7799, 28491, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7800, 28492, 'Metronidazole (topical)', 'Alcoholism', 'Metronidazole may be systemically absorbed when applied to the skin or mucosal membranes.  A disulfiram-like reaction has been reported in patients who consume alcohol during treatment with oral metronidazole.  Symptoms include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension.  Therapy with topical metronidazole should be administered cautiously in patients who might be prone to acute alcohol intake.  Patients should be instructed to avoid alcohol-containing products during therapy and for at least 48 hours after the last dose.', '2', '', 'DDInter', 0);
